Gemini Therapeutics is a precision medicine company focused on the development of new therapies for dry AMD.
We See Disease Differently
We are using our understanding of genetics and biology to identify patients who are at high risk of developing AMD. By identifying and defining genetically subpopulations our work will enable a precise understanding of a patient’s specific disease. This will allow physicians to provide patients with access to specifically targeted and effective medicines.
We are applying our insights in genetics and biology to pioneer first-in-class medicines to restore regulation of the complement system in the eye and throughout the body.
At Gemini Therapeutics, we see a future where genetics enable identification of the correct therapeutic for each specific AMD patient.